Профиль Micro Therapeutics Inc. (MTI)
Micro Therapeutics provides invasive medical devices for the diagnosis and treatment of vascular diseases. It provides devices pertaining to the treatment of neurovascular disorders of the brain associated with stroke. It is also focused on the treatment of peripheral vascular disease, including blood clot therapy in hemodialysis access grafts, arteries, and veins. Its neurovascular product portfolio includes Sapphire and Sapphire NXT detachable coils that were developed to treat brain aneurysms; Onyx, which is a liquid embolic that was developed to treat brain aneurysms and arterial-venous malformations; and delivery products, including guidewires, balloon catheters, and micro catheters, and more. It also provides a mechanical thrombolytic device for interventional clot disruption and dissolution. Micro Therapeutics was established in 1968, based in Irvine, California. It delivers its products to radiologists and neuroradiologists primarily in the United States, Canada, the European Union, and Japan. Micro Therapeutics currently operates as a subsidiary of Covidien plc.